[Form 4] Medtronic plc Insider Trading Activity

Rhea-AI Filing Summary

Medtronic insider stock sales reported. The reporting person, EVP & President Cardiovascular Harry "Skip" Kiil, sold a total of 8,605 ordinary shares in two transactions on 09/03/2025 at prices of about $91.58 and $91.59. After these dispositions the reporting person beneficially owns 35,615 ordinary shares, held directly. The Form 4 was submitted to disclose these non-derivative sales and the change in beneficial ownership.

Positive

• None.

Negative

• Insider sold 8,605 shares, reducing direct beneficial ownership to 35,615 shares
• Dispositions at approximately $91.58–$91.59 represent realized share sales by a senior executive

Insights

Financial Analyst

TL;DR: A senior executive sold 8,605 shares, trimming direct holdings to 35,615 shares; transaction sizes are modest for a large-cap issuer.

The sales are non-derivative dispositions at market-like prices near $91.6 per share, indicating routine cashing-out rather than option exercise or hedging activity. The change reduces direct ownership but does not itself indicate operational change. Investors should note the precise share counts and prices disclosed.

Corporate Governance Expert

TL;DR: Insider reported standard Form 4 sales; disclosure appears complete and uses the required signature-by-attorney-in-fact.

The filing shows two sale transactions reported on one line each, with clear post-transaction beneficial ownership. There is no derivative activity disclosed and no indication of a Rule 10b5-1 plan checked. From a governance perspective the report meets Section 16 disclosure requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIIL HARRY SKIP

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MN 55432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President Cardiovascular

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/03/2025		S		8,405	D	$91.58	35,815	D
Ordinary Shares	09/03/2025		S		200	D	$91.59	35,615	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Medtronic insider Harry Skip Kiil report (MDT)?

The Form 4 reports two sales totaling 8,605 ordinary shares on 09/03/2025 at about $91.58 and $91.59 per share.

How many Medtronic shares does the reporting person own after the transactions?

The reporting person beneficially owns 35,615 ordinary shares following the reported dispositions.

Were any derivative securities (options, warrants, puts/calls) reported in this Form 4?

No. Table II for derivative securities contains no entries, indicating no derivative transactions were reported.

What is the reporting person's role at Medtronic (MDT)?

The reporting person is listed as EVP & President Cardiovascular, and the filing indicates an officer relationship.

Does the Form 4 indicate a 10b5-1 trading plan or other plan-based transaction?

No checkbox or explanation in the filing indicates these sales were made pursuant to a Rule 10b5-1 plan.